US initiation of eye macular degeneration tracking research
February 28, 2018 Source: Science and Technology Daily
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];According to the latest news from the National Institutes of Health (NIH), a new clinical study led by the National Institute of Ophthalmology (NEI) will track 500 people over a five-year period to understand changes in early age-related macular degeneration (AMD). .
AMD is the leading cause of visual impairment and loss in people over the age of 50 in the United States. NEI hopes to observe intraocular structures and measure their function through the latest technology to identify biomarkers of disease progression before the disease progresses to the advanced stage and causes vision loss.
Emily 褚, director and chief research officer of the NEI Department of Epidemiology and Clinical Applications, said: "The results of the study help to understand the underlying biological mechanisms of disease transition from early to late stages, thus developing treatment options to prevent its progression. This will be Public health has a huge impact."
10%-20% of early AMD patients will progress to advanced stage within 5 years. Because AMD is a complex disease, it is difficult to predict which factors will affect its progress due to many factors such as age, family history, genetics and health behavior. The study will track 200 eyes of early-stage AMD patients with subretinal yellowish deposits, 200 patients with early reticular nodules, and 100 age-matched disease-free control participants. All participants will receive conventional spectral-domain optical coherence tomography (SD-OCT), which displays a high-resolution cross-sectional view of the retina and can even detect the volume of the drusen (a lesion that causes AMD) over time. And the small changes that have occurred. In addition, the visual function of the subject will be measured by dark-adapted fundus visual field measurement, which measures the light sensitivity of a specific part of the retina after the human eye adapts to the dark; another dark-adapted visual test is useful for assessing nighttime visual impairment. .
Ideally, the researchers hope to find the correlation between genes and AMD progression by analyzing the participants' DNA. To date, scientists have identified a total of 52 independent genetic variants associated with AMD, and further research is needed to determine how mutations affect disease progression. (Reporter Fang Linlin)
Pain Relief Patch for Breast
[Name] Medical Cold Patch
[Package Dimension] 10 round pieces
The pain relief patch is composed of three layers, namely, backing lining, middle gel and protective film. It is free from pharmacological, immunological or metabolic ingredients.
[Scope of Application] For cold physiotherapy, closed soft tissue only.
[Indications]
The patches give fast acting pain relief for breast hyperplasia, breast fibroids, mastitis, breast agglomera tion, swollen pain.
[How To Use a Patch]
Please follow the Schematic Diagram. One piece, one time.
The curing effect of each piece can last for 6-8 hours.
[Attention]
Do not apply the patch on the problematic skin, such as wounds, eczema, dermatitis,or in the eyes. People allergic to herbs and the pregnant are advised not to use the medication. If swelling or irritation occurs, please stop using and if any of these effects persist or worsen.notify your doctor or pharmacist promptly. Children using the patch must be supervised by adults.
[Storage Conditions]
Store below 30c in a dry place away from heat and direct sunlight.
Pain Relief Patch For Breast,Pain Relief Plaster For Breast,Relief For Breast Pain,Pad Relief Patch For Breast
Shandong XiJieYiTong International Trade Co.,Ltd. , https://www.sdxjmedical.com